CLEMSON — A new company emerging from Clemson University research aims to commercialize innovative genetic sensing technology, according to the university Research Foundation.

Tiger Bioanalytics, led by Guigen Zhang of Clemson University, is developing a cost-effective way to more accurately conduct gene sequencing. The goal is to sequence a whole genome using DNA from a single cell in a short period of time with high accuracy at a low cost. Tiger Bioanalytics’s technology promises a more accurate and affordable approach.

“The new technology that we are developing aims to provide a better way to discriminate nucleotides in a solid-state device such that rapid, affordable and accurate genomic sequencing can be done routinely to improve our health and quality of life,” Zhang said. “Our technology will not only impact the genomic market but also benefit biomedical research as well as global-health initiatives.”

The background research has been supported by $100,000 research funding from the Bill and Melinda Gates Foundation and, more recently, Tiger Bioanalytics received $25,000 in seed money from SC Launch. Zhang is seeking additional capital and partners with expertise in genetic technology commercialization.